SPP2

Across TCGA pan-cancer cohorts, SPP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPP2 data layer compared with 15 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where SPP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.227	0.532	<.001	34	view →
LUAD	OS	Tertile	III,IV	0.227	1.000	.003	20	view →
UCEC	DFS	Quartile	III,IV	0.411	1.000	.040	8	view →
LSCC	DFS	Tertile	All	0.882	0.677	.024	5	view →
CCRCC	DFS	Median	All	0.842	0.651	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPP2–PDAC (DFS)

Open the PDAC breakdown →